Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. SPY
4. ORCL
5. CRCL
6. V
7. GE
8. ASML
9. SPIR
10. NVDA

Go back to Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial
(NASDAQ: CRVS) Delayed: 14.39 --0 (-0%)
Previous Close $14.39    52 Week High $17.77 
Open $14.39    52 Week Low $9.63 
Day High $14.39    P/E N/A 
Day Low $14.39    EPS $0.00 
Volume 120